權威金融(00397.HK)年度純利增247.95%至1.54億港元
格隆匯3月26日丨權威金融(00397.HK)公吿,截至2021年12月31日止12個月,集團錄得收益約9572.1萬港元,同比減少5.89%;公司擁有人應占溢利約1.54億港元,同比增加247.95%;基本每股收益5.52港仙。董事會不建議派付末期股息。
業績大幅增長主要是由於集團整體毛利增長及集團對香港上市證券的投資產生按公平值計入損益之金融資產之公平值變動收益約1.471億港元所致。
於年度內,集團的現金狀況保持強勁,銀行結餘及現金合共於2021年12月31日約為1.530億港元(2020年:2.045億港元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.